Kidney cancer theranostics · First-in-human research
68Ga/177Lu-NYM096: An Early Theranostic Strategy for Clear Cell Kidney Cancer
On 26 August 2026, the Society of Nuclear Medicine and Molecular Imaging highlighted a first-in-human study of a CAIX-targeted PET and radioligand-therapy pair for metastatic clear cell renal cell carcinoma. The report is scientifically promising, but it describes only two treated patients: NYM096 remains experimental and is not established standard care.
Early signal · important limitation
Promising molecular targeting, but only two patients.
The study supports further investigation—not a claim of proven efficacy. Gastric radiation exposure was the main safety challenge and included one grade 3 event.
Read the SNMMI research update ↗What is NYM096?
NYM096 is a small molecule designed to bind carbonic anhydrase IX (CAIX), a target commonly overexpressed in clear cell renal cell carcinoma. The gallium-68 form is intended to identify CAIX-positive disease on PET; the lutetium-177 form uses the same targeting molecule to deliver beta radiation.
This paired imaging-and-treatment approach is the central idea of theranostics: first demonstrate that a tumour expresses the target, then consider treatment using a therapeutic radionuclide attached to the corresponding ligand.
What did the study examine?
The research combined laboratory and mouse studies with a prospective first-in-human assessment in people with metastatic clear cell renal cell carcinoma after standard therapy. Serial 68Ga-NYM096 PET imaging and dosimetry were used to evaluate tumour targeting.
Patients with CAIX-positive disease could proceed to 177Lu-NYM096 in a 3+3 dose-escalation design beginning at 1.85 GBq. The published report describes treatment in two patients, so all clinical findings must be interpreted as preliminary.
What were the early findings?
Both patients showed high tumour uptake on PET, with reported maximum standardised uptake values reaching 330 at one hour. Follow-up imaging suggested tumour responses after treatment.
The authors did not report kidney, liver or pancreatic toxicity in these two patients. These observations are useful for designing larger studies, but they cannot establish response rates, durability, survival benefit or comparative effectiveness.
The principal safety limitation
Physiological stomach uptake produced clinically important radiation exposure. The first patient experienced grade 1 gastric adverse effects and anaemia; the second developed grade 3 radiation-induced gastritis.
The investigators identified gastric toxicity as a major challenge. Future development will require larger safety datasets and strategies to reduce stomach dose before the risk-benefit balance can be understood.
What this means for patients now
- NYM096 is investigational and should not be described as an approved or routinely available kidney-cancer therapy.
- A two-patient report is proof-of-concept research, not evidence sufficient to replace established systemic treatments.
- Patients with metastatic kidney cancer should discuss evidence-based options and clinical trials with their oncology team.
- Any future Malaysian availability would require appropriate regulatory, radiopharmacy and radiation-safety pathways.
Frequently asked questions
Questions patients often ask
Is NYM096 an approved treatment for kidney cancer?
No. 68Ga/177Lu-NYM096 remains investigational. The published first-in-human report included only two treated patients and does not establish routine clinical benefit, regulatory approval or availability in Malaysia.
How does the NYM096 theranostic pair work?
NYM096 targets carbonic anhydrase IX (CAIX), which is commonly overexpressed in clear cell renal cell carcinoma. Gallium-68-labelled NYM096 is used for PET imaging, while lutetium-177-labelled NYM096 is intended to deliver beta radiation to CAIX-positive tumour tissue.
Did the first-in-human study prove that NYM096 works?
No. The study reported encouraging imaging and tumour-response signals in two patients, but that sample is far too small to establish efficacy or compare NYM096 with standard treatments.
What was the main safety concern?
Physiological stomach uptake was the principal concern. One patient had mild gastric effects and anaemia; the second developed grade 3 radiation-induced gastritis. Larger studies and improved stomach protection or dosimetry are needed.
Is NYM096 available in Malaysia?
This early study does not establish Malaysian registration or clinical availability. Patients should not delay proven kidney-cancer treatment while seeking an investigational radiopharmaceutical.
Clinical references
This patient information was prepared with reference to authoritative clinical and professional sources.